MedTrace Logo

US-CT Fusion for Post Implant Dosimetry

NCT03692104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2020-01-27

No results posted yet for this study

Summary

Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred. This is not always available due to financial restrictions. This study explores the possibility of post implant US-CT fusion to improve contouring accuracy and potentially replace the use of MR-CT fusion.

Conditions

Interventions

DIAGNOSTIC_TEST

transrectal ultrasound

Use of US for post implant quality assessment

Sponsors & Collaborators

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Francois Bachand, MD · BC Cancer

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-03
Primary Completion
2018-02-28
Completion
2019-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692104 on ClinicalTrials.gov